Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
TargetMol | Tags Autophagy
TargetMol | Tags GPCR/G Protein
TargetMol | Tags Immunology/Inflammation

CXCR

The CXCR signaling pathway family mainly comprises chemokines and chemokine receptors and CXCR consists of about 330 amino acids. The seven transmembrane regions divide the molecule into an extracellular free N-terminus, three extracellular loops, three intracellular loops, and several C-terminal portions.

  • SX-682
    T84971648843-04-2
    SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Artemotil
    T332775887-54-6
    Artemotil (SM-227) is a new, fast-acting antimalarial drug.
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AMD-070 hydrochloride
    T22565880549-30-4
    AMD-070 hydrochloride is a CXCR4 antagonist, is useful for Anti HIV.
    • $45
    In Stock
    Size
    QTY
  • NUCC-390
    T122691060524-97-1In house
    NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo.
    • $151
    In Stock
    Size
    QTY
  • ALX 40-4C acetate
    TP1364L
    ALX 40-4C acetate is a CXCR4 inhibitor of the chemokine receptor (Ki = 1 μM) and suppresses the replication of X4 strains of HIV-1. ALX 40-4C acetate is an antagonist of the APJ receptor (IC50 = 2.9 μM).
    • $221
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • rac-NBI-74330
    T26035473722-68-8In house
    rac-NBI-74330 is an effective and selective CXCR3 antagonist.
    • $88
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Elubrixin
    T11179688763-64-6In house
    Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel disease and airway inflammation. Elubrixin is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.
    • $195
    In Stock
    Size
    QTY
  • ATI-2341 acetate(1337878-62-2 free base)
    T6764L
    ATI-2341 acetate is an effective allosteric agonist of CXCR4, it activates Gα1 instead of Gα13. ATI-2341 acetate activates inhibitory heterotrimeric G protein (GI) to promote the inhibition of cAMP production and induce calcium mobilization.
    • $131
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CTCE 9908 acetate
    TP2051L
    CTCE 9908 acetate is an antagonist of CXCR4 and inhibits migration in CXCR4-expressing ovarian cancer cells.
    • $257
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ac-Pro-Gly-Pro-OH
    T76662292171-04-1
    Ac-Pro-Gly-Pro-OH is an acetyl-modified tripeptide compound that acts as a CXCR2 agonist.Ac-Pro-Gly-Pro-OH exhibits bactericidal and anti-inflammatory activity, inhibits apoptosis of immune cells, and suppresses the production of pro-inflammatory cytokines.Ac-Pro-Gly-Pro-OH has been used in the study of sepsis and inflammation in the lungs.
    • $38
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Motixafortide TFA(664334-36-5,Free)
    T14665L
    Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ~1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
    • $117
    In Stock
    Size
    QTY
  • LY2510924 acetate(1088715-84-7 free base)
    T15805L
    Ly2510924 acetate is an potent and selective CXCR4 antagonist. It prevents the binding of SDF-1 to CXCR4 with an IC50 of 0.079 nM.
    • $162
    In Stock
    Size
    QTY
  • TC14012 acetate
    TP2112L
    TC14012 acetate is a serum-stable derivative of T140 which is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 is also a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-cancer activity and anti-HIV activity.
    • $77
    In Stock
    Size
    QTY
  • AZD8309
    T25131333742-48-6In house
    AZD8309 is a potent, orally available antagonist of the chemokine receptor CXCR2 that regulates neutrophil transport, significantly reduces MPO in the pancreas and lung, and decreases trypsin and elastase activity in the pancreas.AZD8309 can be used to study a range of inflammatory diseases.
    • $129
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CXCR2-IN-1
    T109051873376-49-8In house
    CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
    • $73
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Burixafor hydrobromide
    T106351191450-19-7In house
    Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • SB225002
    T1955182498-32-4
    SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Mogamulizumab
    T767821159266-37-1
    Mogamulizumab (KW-0761) is a monoclonal antibody against T cell CC chemokine receptor 4. Mogamulizumab has anticancer activity, eliminating tumor cells through antibody dependent cytotoxicity (ADCC), and can be used to study cancer, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).
    • $476
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • FC131 TFA (606968-52-9 free base)
    TP1348842166-42-1
    FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AMD 3465 hexahydrobromide
    T7208185991-07-5
    AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • (+/-)-Vestitol
    TN522756701-24-7
    Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to be applied in the pharmaceutical and food industries. Vestitol inhibits neutrophils migration
    • $2,149
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Eldelumab
    T76741946414-98-8
    Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10.Eldelumab has anti-inflammatory activity and selectively binds to CXCL10 and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.
    • $239
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Tannic acid
    T08011401-55-4
    Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Pentixafor
    T790701341207-62-2
    Pentixafor is a peptide that selectively targets the CXCR4 receptor and can be labeled with Gallium-68 (68Ga) for visualization using positron emission tomography (PET) imaging [1].
    • Inquiry Price
    Size
    QTY
  • MSX-130
    T40334051-59-6
    MSX-130 is CXCR4 Antagonist.
    • $44
    In Stock
    Size
    QTY
  • SRT3190
    T169331204707-73-2
    SRT3190 is an antagonist of CXCR2.
    • $142
    5 days
    Size
    QTY
  • Mavorixafor
    TQ0174558447-26-0
    Mavorixafor (AMD-070) is an effective and selective antagonist of CXCR4, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells (IC50 = 1 nM) and PBMCs (IC50 = 9 nM).
    • $64
    In Stock
    Size
    QTY
  • CXCR7 antagonist-1
    T390781613021-99-0
    CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7. CXCR7 antagonist-1 prevents tumor cell proliferation and tumor formation and can be used in studies about inflammatory diseases.
    • $188
    In Stock
    Size
    QTY
  • Balixafortide TFA (1051366-32-5 free base)
    TP2141
    Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium fl
    • $153
    Backorder
    Size
    QTY
  • Delmetacin
    T6805216401-80-2
    Delmetacin (Demethacin) is a non-steroidal anti-inflammatory compound with anti-inflammatory and analgesic activity and inhibitory effects on the CXC chemokine receptor CXCR1.
    • $75
    In Stock
    Size
    QTY
  • E70K
    T80525
    E70K, a CXCL8 C-terminal peptide, features a lysine (K) substitution for glutamic acid (E) at position 70 and has demonstrated the ability to attenuate neutrophil adhesion and migration in the context of inflammation [1].
    • Inquiry Price
    Size
    QTY
  • IT1t dihydrochloride
    T11693L1092776-63-0
    IT1t dihydrochloride inhibits CXCL12/CXCR4 interaction with IC50 of 2.1 nM. IT1t dihydrochloride is an antagonist of CXCR4.
    • $35
    In Stock
    Size
    QTY
  • VUF11207 fumarate
    T133241785665-61-3
    VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).
    • $36
    In Stock
    Size
    QTY
  • AZD8797
    T14384911715-90-7
    AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2, and potentially protects against SARS-CoV-2-induced neuronal damage, preventing worsening of nociceptive sensitization and microglial activation in a migraine model of rats following seizures.
    • $83
    In Stock
    Size
    QTY
  • SCH 563705
    T16864473728-58-4
    SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
    • $2,270
    Backorder
    Size
    QTY
  • ITIC-4F
    T193852097998-59-7
    ITIC-4F, an indacenodithienothiophene (IDTT)-based postfullerene electron acceptor, exhibits wide applicability in high-efficiency binary and ternary single-junction as well as tandem polymer solar cells (PSCs).
    • Inquiry Price
    Size
    QTY
  • JMS-17-2
    T58491380392-05-1
    JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).
    • $34
    In Stock
    Size
    QTY
  • Balixafortide
    TP2141L1051366-32-5
    Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2]. Balixafortide blocks β-arresti
    • Inquiry Price
    Size
    QTY
  • ML339
    T97212579689-83-9
    ML339 a selective inhibitor of CXCR6(IC50 = 140 nM) with no response when screened against CXCR5 and CXCR4.
    • $38
    In Stock
    Size
    QTY
  • CXCR4-IN-1
    T790592304750-48-7
    CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic retinopathy, and inflammation [1].
    • $1,520
    Backorder
    Size
    QTY
  • DOTA-CXCR4-L
    T80216
    DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer [1].
    • Inquiry Price
    Size
    QTY
  • VUF-11222
    T350851414376-84-3
    VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.
    • $143
    In Stock
    Size
    QTY
  • Plerixafor octahydrochloride
    T1776L155148-31-5
    Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.
    • $42
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Motixafortide
    T14665664334-36-5
    Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
    • $747
    Backorder
    Size
    QTY
  • TAK-779
    T7499229005-80-5
    TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).
    • $38
    In Stock
    Size
    QTY
  • SRT3109
    T30471204707-71-0
    SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
    • $133
    In Stock
    Size
    QTY
  • MSX-127
    T40326616-56-4
    MSX-127 elicites positive response in peptide CXCR4.
    • $68
    In Stock
    Size
    QTY
  • NUCC-390 dihydrochloride (1060524-97-1 free base)
    T12269L
    NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
    • Inquiry Price
    Size
    QTY
  • Ulocuplumab
    T767941375830-34-4
    Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)
    • $247
    In Stock
    Size
    QTY
  • Reparixin L-lysine salt
    T12705266359-93-7
    Reparixin L-lysine salt (Repertaxin L-lysine salt) is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.
    • $39
    In Stock
    Size
    QTY